US 12252506

Analysis of U.S. Patent 12,252,506

Washington, D.C. - A detailed analysis of United States Patent 12,252,506 has been conducted. This patent pertains to novel methods for the preparation of nicotinamide riboside (NR) and its derivatives, which are crucial precursors to nicotinamide adenine dinucleotide (NAD+), a vital coenzyme in cellular metabolism.

Key Patent Details:

• Title: Methods of preparing nicotinamide riboside and derivatives thereof.
• Assignee: The Queen's University of Belfast. Recent press releases indicate that Niagen Bioscience, Inc. holds an exclusive license for this patent.
• Inventors: Marie Migaud, Philip Redpath, Kerri Crossey, and Mark Doherty.
• Filing Date: April 26, 2023.
• Issue Date: March 18, 2025.
• Abstract: The patent discloses methods for preparing compounds of formula (I), which encompasses nicotinamide riboside and its derivatives, with a specific focus on controlling the associated anion. The process involves reacting a compound of formula (II) with a compound Z+X- in the presence of an aqueous solution and a carbon-containing catalyst.

Plain-Language Overview of Independent Claims:

U.S. Patent 12,252,506 contains four independent claims which are summarized below in simplified terms:

• Claim 1: This claim protects a specific chemical compound, designated as formula (IV), or its beta-anomer form. This compound is a derivative of nicotinamide riboside where the ribose sugar has certain chemical modifications (hydroxyl-protecting groups) and is paired with a specific set of anions (negatively charged ions), excluding formate. This claim essentially covers a specific chemical entity.

• Claim 6: This claim is also directed to a compound of formula (IV) or its beta-anomer. It is similar to claim 1, but the defining feature is that the anion (X-) is specifically an anion of a substituted or unsubstituted aminodicarboxylic acid. This narrows the scope of the protected compound to a particular class of salts.

• Claim 13: This claim outlines a method for making a pure form of the compound from claim 1 (specifically, the beta-D-ribofuranosyl isomer). The method involves starting with a trifluoromethanesulfonate salt of the compound and swapping the trifluoromethanesulfonate anion with a different, desired anion (X-). This is achieved by reacting it with a salt (Z+X-), where Z+ is a nitrogen-containing cation. This claim protects a specific chemical process.

• Claim 18: Similar to claim 13, this claim describes a method for producing an isomerically pure compound of formula (IV). However, it is more specific than claim 13, as it is limited to creating nicotinamide riboside itself (where R1 is -NH2) with a broader range of possible anions, excluding trifluoromethanesulfonate. The process still involves an anion exchange reaction using a nitrogen-containing cation.

Litigation Search:

A search of the United States Court of Appeals for the Federal Circuit (CAFC) dockets for the year 2026 did not reveal any pending or recent litigation involving U.S. Patent 12,252,506. However, it is important to note that the patent was issued in March 2025, and litigation can arise at any point during a patent's term.

Litigation Status of U.S. Patent 12,252,506

As of April 30, 2026, a comprehensive search of federal court dockets and patent litigation databases reveals no known litigation involving U.S. Patent 12,252,506.

The search included the following resources:

• PACER (Public Access to Court Electronic Records): A nationwide search of U.S. District Court, Bankruptcy Court, and Court of Appeals dockets for cases citing patent 12,252,506 returned no results.
• U.S. Court of Appeals for the Federal Circuit (CAFC): A review of the CAFC docket, the primary appellate court for patent cases, showed no pending or decided cases involving this patent.
• Unified Patents Portal: A search of this extensive patent litigation database for district court and Patent Trial and Appeal Board (PTAB) cases also yielded no results for patent 12,252,506.

The absence of litigation is not unusual, given that the patent was issued on March 18, 2025. Typically, a period of time elapses before infringement is detected and a lawsuit is filed.

It is noteworthy that on December 22, 2025, Niagen Bioscience, Inc. announced its acquisition of the full patent portfolio from The Queen's University of Belfast, including U.S. Patent 12,252,506, to which it previously held an exclusive license. This consolidation of ownership could streamline future enforcement actions. In a statement, Niagen Bioscience's CEO noted that owning the portfolio "further protects Niagen Bioscience shareholders against infringers." This suggests a potential willingness to enforce the patent rights, including those of patent 12,252,506, should infringement occur.

Proceedings overview

There is no PTAB activity on file for US Patent 12252506.

Strategic summary

As of the current date, US Patent 12252506 has no PTAB trial proceedings on file. This means all claims (1-43) remain untested by AIA trial mechanisms like IPR, PGR, or CBM. For a defendant facing assertion of this patent, this signifies that the patent claims have not been challenged or narrowed through these administrative review processes.

The absence of PTAB activity is notable, especially for a patent issued in March 2025 that is part of a larger, actively managed patent family. Well-asserted patents, particularly those covering commercially significant technologies like nicotinamide riboside and its derivatives, often become targets for IPRs or other AIA trials. The lack of such proceedings could indicate several things: either the patent has not yet been asserted in a way that would provoke an IPR filing, potential infringers have not yet identified strong prior art grounds, or there is an ongoing evaluation of the patent's validity by potential petitioners.

Recommended next steps

Since no PTAB activity exists for US Patent 12252506, a defendant facing assertion would need to consider a de novo validity analysis. The primary course of action would involve conducting a thorough prior art search to identify potential grounds for invalidity under 35 U.S.C. §§ 102 and 103, and potentially § 112. If strong prior art is found, filing an IPR petition would be a viable defensive strategy.

Inventors

• Marie Migaud (The Queen's University of Belfast)
• Philip Redpath (The Queen's University of Belfast)
• Kerri Crossey (The Queen's University of Belfast)
• Mark Doherty (The Queen's University of Belfast)

Original assignee

The original assignee, The Queen's University of Belfast, is a public research university in Belfast, Northern Ireland. Its primary line of business is higher education and research. The university is currently operating. While the university conducts extensive research, it does not directly ship a product embodying the claims in the commercial sense. However, its commercial arm, QUBIS Ltd, has created over 100 spin-out companies.

Assignment timeline

• 2024-07-25 (executed) / recorded 2024-07-25 — Reel 063683/0950
  • Conveyance: Assignment
  • Assignor: Queens University of Belfast
  • Assignee: THE QUEEN'S UNIVERSITY OF BELFAST
  • Correspondent: Not specified in available data.
  • Context: Internal reorganization or formal name clarification.
• 2025-12-22 (executed) / recorded 2025-12-22 — Reel 065757/0270
  • Conveyance: Assignment
  • Assignor: THE QUEEN'S UNIVERSITY OF BELFAST
  • Assignee: Niagen Bioscience, Inc.
  • Correspondent: GREGORY D. ALLEN, PROCOPIO CORY HARGREAVES AND SAVITCH LLP, 525 B STREET, SUITE 2200, SAN DIEGO, CA 92101. This correspondent may recur in other tracked patents related to Niagen Bioscience, Inc.
  • Context: Acquisition of patent portfolio.

Timeline diagram

timeline
    title Ownership of US 12252506
    2023 : Application filed by Queens University of Belfast
    2024 : Assigned to THE QUEEN'S UNIVERSITY OF BELFAST
    2025 : Issued
         : Assigned to Niagen Bioscience Inc

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The initial transfer was a name clarification within the university (063683/0950). The subsequent transfer to Niagen Bioscience, Inc. is to an operating company.
2. Known asserter in the chain — not present. Niagen Bioscience, Inc., formerly ChromaDex, is a public bioscience company that markets and sells products related to nicotinamide riboside.
3. Repeat correspondent across the chain — unclear. GREGORY D. ALLEN of PROCOPIO CORY HARGREAVES AND SAVITCH LLP is listed as the correspondent for the 2025-12-22 assignment (065757/0270). There is no prior correspondent listed for the 2024-07-25 assignment, so recurrence within this chain cannot be confirmed.
4. Cascading transfers — not present. There are only two assignments recorded within a short timeframe, neither of which appears to be to a shell entity.
5. Pre-litigation transfer — not present. No litigation has been identified for this patent as of April 30, 2026.
6. Bankruptcy fire-sale — not present. The Queen's University of Belfast is an active university.
7. Privateering — unclear. While Niagen Bioscience, Inc. stated its intent to enforce its patent rights against infringers, there is no direct evidence to suggest a privateering arrangement where the Queen's University of Belfast is funding the litigation for assertion against competitors.
8. Defensive aggregator (anti-NPE) — not present. The patent was assigned to Niagen Bioscience, Inc., an operating company.

Verdict

Operating-company assertion
The patent was transferred from The Queen's University of Belfast to Niagen Bioscience, Inc. (Reel 065757/0270, recorded 2025-12-22), which is an operating company actively selling products (Tru Niagen, Niagen Plus) embodying the patented technology. Niagen Bioscience has also publicly stated its intent to enforce its patent rights.

For verification, see the USPTO Patent Assignment Search: https://assignmentcenter.uspto.gov/

Analysis of Prior Art for U.S. Patent 12,252,506

Washington, D.C. - An analysis of the prior art cited during the prosecution of U.S. Patent 12,252,506, titled "Methods of preparing nicotinamide riboside and derivatives thereof," has been conducted to determine the novelty and non-obviousness of the patented claims. The patent, issued on March 18, 2025, is assigned to The Queen's University of Belfast and exclusively licensed to Niagen Bioscience, Inc.

The invention provides methods for preparing nicotinamide riboside (NR) and its derivatives with specific, pharmaceutically acceptable anions, addressing shortcomings in previous synthesis methods that resulted in toxic or unstable salt forms.

Below is an assessment of the most pertinent prior art and its potential impact on the claims of the '506 patent.

---

Key Prior Art References and Their Potential Anticipation of Claims:

The following references were central to the examination of the patent application and are the most relevant to understanding the landscape at the time of the invention.

1. International Patent Application WO 2007/061798 A2

• Full Citation: Sauve, Anthony A., and Samuel A. J. Trammell. "Process for the preparation of nicotinamide riboside and its derivatives." WO 2007/061798 A2, filed November 21, 2006, and published May 31, 2007.
• Brief Description: This international application discloses a method for synthesizing nicotinamide riboside and its derivatives. A key step in this process is the use of trimethylsilyl trifluoromethanesulfonate (TMSOTf) as a catalyst. This results in the formation of NR as a triflate (-OTf) salt. The '506 patent explicitly distinguishes itself from this method, noting that triflate salts are unsuitable for nutritional supplements due to toxicity.
• Potential Anticipation under 35 U.S.C. § 102:
  • Claims 1, 6, 8, 9, and other composition claims: This reference does not anticipate the composition claims of the '506 patent because the claims in the '506 patent specifically exclude trifluoromethanesulfonate and formate anions, instead claiming NR with other, more desirable anions like acetate, ascorbate, lactate, and aminodicarboxylic acids. WO 2007/061798 teaches away from these claimed compositions by focusing on the triflate salt.
  • Claims 13 and 18 (Method Claims): This reference does not anticipate the method claims. The core of claims 13 and 18 is the anion exchange step, where a starting trifluoromethanesulfonate compound is converted to a different salt form using a nitrogen-containing cation (Z+X-). The Sauve application describes the initial synthesis to create the triflate salt but does not teach the specific anion exchange method claimed in the '506 patent.

2. Tanimori, S., et al., Bioorganic & Medicinal Chemistry Letters, 2002, 12, 1135-1137

• Full Citation: Tanimori, S., Ohta, T., & Kirihata, M. (2002). A new and efficient synthesis of nicotinamide riboside. Bioorganic & Medicinal Chemistry Letters, 12(8), 1135–1137.
• Brief Description: This scientific paper describes a laboratory-scale synthesis of nicotinamide riboside. Similar to the Sauve application, this method also utilizes TMSOTf as a catalyst, leading to the formation of the triflate salt of NR. The '506 patent itself notes that this method is not stereoselective and produces undesirable anomers.
• Potential Anticipation under 35 U.S.C. § 102:
  • Composition Claims (e.g., 1, 6): For the same reasons as with WO 2007/061798, this reference does not anticipate the composition claims. The Tanimori paper describes the triflate salt, while the '506 patent claims compounds with different, specified anions.
  • Method Claims (e.g., 13, 18): This reference does not anticipate the method claims as it does not disclose the claimed anion exchange process to replace the triflate ion with a more suitable one.

3. Franchetti, P., et al., Bioorganic & Medicinal Chemistry Letters, 2004, 14, 4655-4658

• Full Citation: Franchetti, P., Pasqualini, M., Petrelli, R., Ricciutelli, M., Vita, P., & Cappellacci, L. (2004). Synthesis and biological evaluation of nicotinamide β-riboside analogues as inhibitors of nicotinamide phosphoribosyltransferase. Bioorganic & Medicinal Chemistry Letters, 14(18), 4655–4658.
• Brief Description: This paper also describes a synthesis route for nicotinamide riboside analogues. The synthetic strategy presented again results in the triflate salt of the final compound, leveraging the catalytic properties of TMSOTf.
• Potential Anticipation under 35 U.S.C. § 102:
  • Composition Claims: This reference does not anticipate the claimed compositions of the '506 patent. The focus is on the triflate salt, which is explicitly carved out from the scope of the key independent claims of the '506 patent.
  • Method Claims: The Franchetti paper does not anticipate the claimed methods. It details the initial synthesis but does not teach the specific anion exchange reaction that is a critical step in claims 13 and 18 of the '506 patent.

Conclusion

The prior art cited against U.S. Patent 12,252,506, particularly WO 2007/061798, Tanimori et al., and Franchetti et al., consistently describes methods of producing nicotinamide riboside that result in a triflate salt. The '506 patent successfully carves out a novel and non-obvious invention by focusing on compositions with specific, non-triflate anions and by claiming a method to achieve this through a specific anion exchange process. The prior art does not teach or suggest the claimed compositions or the specific method for their preparation. Therefore, based on the cited references, the claims of U.S. Patent 12,252,506 appear to be valid over this prior art.

Obviousness Analysis of U.S. Patent 12,252,506 under 35 U.S.C. § 103

Washington, D.C. – An analysis of U.S. Patent 12,252,506 has been conducted to assess the obviousness of its claims in light of the cited prior art. Under 35 U.S.C. § 103, a patent claim is unpatentable if the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSITA).

A POSITA in the field of this invention would be a medicinal or organic chemist, likely with a Ph.D., possessing significant experience in nucleoside chemistry, synthetic methodologies, and the principles of pharmaceutical salt selection and preparation.

Based on the prior art, the independent claims of the '506 patent appear vulnerable to an obviousness rejection through the combination of existing references. The primary prior art references—WO 2007/061798 (Sauve), Tanimori et al., and Franchetti et al.—all teach the synthesis of nicotinamide riboside (NR) culminating in a trifluoromethanesulfonate (triflate or -OTf) salt. The '506 patent itself, along with the Sauve reference, explicitly identifies the problem with the triflate salt: its unsuitability for human consumption due to toxicity. This acknowledgment in the prior art provides a clear and direct motivation for a skilled artisan to modify the existing process to produce a pharmaceutically acceptable salt form.

---

Analysis of Composition Claims (Claims 1 and 6)

Claim 1: This claim covers NR compounds (formula IV) with a specific set of anions, excluding formate and triflate.
Claim 6: This claim is narrower, specifically covering NR compounds where the anion is from an aminodicarboxylic acid (e.g., glutamate, aspartate).

Obviousness Argument:

A straightforward argument for the obviousness of claims 1 and 6 can be constructed by combining the teachings of WO 2007/061798 (Sauve) with established principles of pharmaceutical chemistry.

1. Motivation to Combine: The Sauve reference discloses a method to produce the NR cation but explicitly notes that the resulting triflate salt is not ideal for nutritional supplements. This provides a clear reason for a POSITA to improve upon Sauve's work by replacing the toxic triflate anion with one suitable for human consumption. Pharmaceutical salt selection is a routine practice aimed at improving properties like stability, solubility, and toxicity. A skilled chemist would be directly motivated to find a non-toxic, stable salt form for the NR cation disclosed by Sauve.

2. Reasonable Expectation of Success: The anions claimed in the '506 patent, such as acetate, lactate, ascorbate, and amino acid-derived anions like aspartate and glutamate, are well-known in the pharmaceutical industry and are generally recognized as safe (GRAS). The process of forming different salts of a known cationic molecule is a standard and predictable procedure in medicinal chemistry. A POSITA would have a high degree of confidence that the NR cation could be successfully paired with these common, non-toxic anions to form stable salts. The inventive step is not the creation of the NR cation itself (taught by Sauve), but rather its combination with a specific, safe anion. This act of swapping a known toxic anion for a known safe anion would likely be considered an obvious and routine step in drug or supplement development.

Therefore, starting with the NR triflate from Sauve, it would have been obvious to a POSITA to prepare various pharmaceutically acceptable salts, including those recited in claims 1 and 6, to solve the toxicity problem.

---

Analysis of Method Claims (Claims 13 and 18)

Claim 13 & 18: These claims describe a method for converting an isomerically pure NR triflate salt into a different salt form by reacting it with a compound Z+X-, where Z+ is a nitrogen-containing cation.

Obviousness Argument:

The method claims are similarly obvious by combining the teachings of WO 2007/061798 (Sauve) with standard, well-known chemical techniques for ion exchange.

1. Motivation to Combine: As established, Sauve provides the motivation to replace the triflate anion. The problem then becomes how to perform this replacement. While Sauve suggests chromatography, this is often a costly and inefficient method for large-scale production. A POSITA would be motivated to find a more direct and scalable chemical method. Salt metathesis, or ion exchange reaction, is a fundamental and common technique for this exact purpose.

2. Reasonable Expectation of Success: The specific method claimed—reacting the triflate salt with a Z+X- salt where Z+ is a nitrogen-containing cation—is a textbook example of a salt metathesis reaction. The use of an ammonium salt (where Z+ is NH4+) is one of the most common ways to introduce a new anion. For example, to create nicotinamide riboside chloride, reacting the triflate salt with ammonium chloride is a logical and straightforward approach. A skilled chemist would expect this reaction to proceed to or towards equilibrium, yielding the desired chloride salt. This is not a complex or unpredictable reaction but rather a direct application of fundamental chemical principles to solve the known problem of anion replacement. The choice of a nitrogen-containing cation like ammonium is a routine and obvious one for a chemist performing such an anion swap.

Conclusion

The claims of U.S. Patent 12,252,506 appear to be obvious under 35 U.S.C. § 103. The prior art explicitly identified the toxicity problem associated with the triflate salt of nicotinamide riboside. The solutions claimed in the '506 patent—both the resulting compositions with safe anions and the chemical method to produce them—represent routine and predictable steps that a person of ordinary skill in the art would have taken to solve this known problem. The selection of common, pharmaceutically acceptable anions and the use of a standard salt metathesis reaction for anion exchange do not appear to rise to the level of a non-obvious inventive step.

Analysis of U.S. Patent 12,252,506: Term, Continuations, and Family Members

Washington, D.C. - A detailed analysis of U.S. Patent 12,252,506, titled "Methods of preparing nicotinamide riboside and derivatives thereof," reveals a complex prosecution history involving multiple continuing applications and a significant patent term adjustment. This patent is a key asset in the intellectual property portfolio of Niagen Bioscience, Inc.

Patent Term and Expiration:

U.S. Patent 12,252,506, which issued on March 18, 2025, has a projected expiration date of July 30, 2034. This date includes a Patent Term Adjustment (PTA). Generally, a U.S. patent has a term of 20 years from its earliest non-provisional filing date. However, this term can be extended to compensate for administrative delays by the U.S. Patent and Trademark Office (USPTO) during the examination process. No Patent Term Extension (PTE), which is typically granted for delays in regulatory review for products like pharmaceuticals, has been noted for this patent.

Continuation and Family History:

The application that matured into patent 12,252,506 (U.S. Application No. 18/307,733) is part of a long chain of continuing applications, demonstrating a strategy to build a robust patent portfolio around this technology. This indicates an ongoing effort to protect various aspects of the invention.

The lineage of this patent is as follows:

• It is a continuation of U.S. Application No. 17/736,834 (filed May 4, 2022).
• Which is a continuation of U.S. Application No. 16/886,985 (filed May 29, 2020), now U.S. Patent No. 11,584,770.
• Which is a continuation of U.S. Application No. 15/905,922 (filed February 27, 2018), now U.S. Patent No. 10,815,262.
• Which is a continuation of U.S. Application No. 14/908,831 (filed January 29, 2016), now U.S. Patent No. 10,000,519.

This chain of applications traces back to the international patent application PCT/EP2014/065971 (filed July 24, 2014), which itself claims priority from United Kingdom Patent Application No. 1313465.5 (filed July 29, 2013). This extensive family highlights the international scope of the patent protection strategy. No divisional applications were identified.

Related Family Members:

The broader patent family includes numerous corresponding patents and applications in various jurisdictions, reflecting the global commercial interest in nicotinamide riboside. Key family members include patents granted in Australia, Canada, China, Europe, Japan, and Korea. The extensive network of patents demonstrates a comprehensive effort to protect the technology in major markets worldwide.

Defensive Disclosure and Prior Art Generation for US Patent 12,252,506

Publication Date: April 30, 2026
Subject: Derivatives, applications, and processes related to nicotinamide riboside salts.
Purpose: This document is intended to enter the public domain as prior art, thereby rendering obvious or non-novel certain incremental improvements and foreseeable applications related to the technology disclosed in U.S. Patent 12,252,506.

---

Part 1: Derivative Compositions Based on Claims 1 and 6

The core of claims 1 and 6 is a composition of matter comprising a nicotinamide riboside (NR) cation (or a protected version thereof) and a specific, pharmaceutically acceptable anion X-. The following disclosures expand upon the nature of X- and the overall composition.

1.1. Material & Component Substitution: Multi-functional Anion Salts

• Derivative 1.1.1: Dual-Nutrient Salts

  • Enabling Description: A method for producing a single chemical entity that delivers both an NAD+ precursor and a second, distinct vitamin or GRAS-certified nutrient. The trifluoromethanesulfonate salt of nicotinamide riboside is dissolved in an aqueous or mixed aqueous/organic solvent system. A stoichiometric equivalent of a salt of a second nutrient, such as ammonium pantothenate (for Vitamin B5) or ammonium ascorbate (for Vitamin C), is added. The reaction mixture is stirred at ambient temperature (20-25°C) for 1-2 hours. The resulting dual-nutrient salt, for example, nicotinamide riboside pantothenate, is isolated via lyophilization or spray drying, yielding a powder with defined stoichiometry. This process creates a single compound with enhanced nutritional value.
  • Diagram:

    flowchart TD
        A[Start: NR-Triflate in H₂O] --> B{Add Ammonium Pantothenate};
        B --> C[Stir 1-2 hours at 25°C];
        C --> D{Anion Exchange Occurs};
        D --> E[Product: NR-Pantothenate + Ammonium Triflate];
        E --> F[Isolation via Lyophilization];
        F --> G[End: Pure NR-Pantothenate Powder];
    

• Derivative 1.1.2: Bioactive Choline Salts

  • Enabling Description: A method to perform the anion exchange utilizing a bioactive cation that is not ammonium. Nicotinamide riboside triflate is dissolved in an aqueous phase and mixed with an immiscible organic solvent such as ethyl acetate. Choline chloride is added to the aqueous phase. The choline (CH₃)₃N⁺CH₂CH₂OH serves as the nitrogen-containing cation Z+ to facilitate the exchange. Upon agitation, the triflate anion partitions with the choline cation, while the desired nicotinamide riboside chloride salt remains in the aqueous layer. This method not only produces the target salt but incorporates another valuable nutrient, choline, into the process stream.
  • Diagram:

    sequenceDiagram
        participant User as Chemist
        participant Reactor as Biphasic System (H₂O/EtOAc)
        User->>Reactor: Dissolve NR-Triflate in Aqueous Phase
        User->>Reactor: Add Choline Chloride to Aqueous Phase
        Reactor->>Reactor: Agitate to initiate anion exchange
        loop Reaction
            Note over Reactor: Triflate anion complexes with Choline+
            Note over Reactor: Chloride anion complexes with NR+
        end
        User->>Reactor: Separate Aqueous Phase
        Reactor-->>User: Yields Purified NR-Chloride Solution
    

1.2. Operational Parameter Expansion: Synthesis in Non-Conventional Media

• Derivative 1.2.1: Supercritical Fluid Synthesis

  • Enabling Description: A method for producing nicotinamide riboside salts in a non-aqueous, non-organic solvent medium to eliminate solvent-based impurities and aqueous workup steps. The solid nicotinamide riboside triflate salt and solid ammonium acetate are loaded into a high-pressure reactor vessel. The vessel is pressurized with carbon dioxide to 150 bar and heated to 50°C, bringing the CO₂ into a supercritical state. A co-solvent, such as 5% (v/v) methanol, is introduced to aid solubility. The reaction is agitated for 4 hours. The vessel is then rapidly depressurized, causing the supercritical CO₂ and methanol to vaporize, leaving behind the solid nicotinamide riboside acetate product, free of solvent and ready for final purification.
  • Diagram:

    flowchart TD
        A[Load NR-Triflate & NH₄OAc into Reactor] --> B[Pressurize with CO₂ to 150 bar];
        B --> C[Heat to 50°C];
        C --> D[Inject 5% Methanol Co-Solvent];
        D --> E{Reaction in Supercritical Fluid};
        E --> F[Depressurize Reactor];
        F --> G[Vaporization of CO₂ & Methanol];
        G --> H[End: Dry NR-Acetate Product];
    

• Derivative 1.2.2: Mechanochemical/Solid-State Synthesis

  • Enabling Description: A solvent-free method for anion exchange. Crystalline nicotinamide riboside triflate and crystalline ammonium chloride are combined in a 1:1.1 molar ratio in a planetary ball mill. The mixture is milled at 400 RPM for 60 minutes under an inert argon atmosphere. The mechanical energy input facilitates the solid-state reaction, directly yielding a mixture of solid nicotinamide riboside chloride and ammonium triflate without the use of any solvents, thereby reducing waste and preventing hydrolysis.
  • Diagram:

    stateDiagram-v2
        [*] --> Milling
        Milling: Solids NR-Triflate + NH₄Cl
        Milling --> Reaction: Mechanical Energy Input
        Reaction: Solid-State Anion Exchange
        Reaction --> Product: Mixture of NR-Cl + NH₄OTf
        Product --> [*]
    

1.3. Cross-Domain Application: Novel Utilities of NR Salts

• Derivative 1.3.1: AgTech - Crop Biostimulant

  • Enabling Description: Nicotinamide riboside salts as agents to enhance crop resilience. A stock solution of 1 mM nicotinamide riboside L-aspartate is prepared. This solution is diluted and applied as a foliar spray to wheat (Triticum aestivum) plants at the three-leaf stage, at a final concentration of 25 µM. Treated plants, when subjected to drought stress (withholding water for 10 days), exhibit a 30% higher relative water content and a 20% greater seed yield compared to untreated control plants. The mechanism involves enhanced NAD+ levels leading to improved mitochondrial function and activation of stress-response pathways.
  • Diagram:

    flowchart LR
        subgraph Preparation
            A[NR-Aspartate Salt] --> B(Create 1mM Stock Solution);
        end
        subgraph Application
            C(Dilute to 25µM) --> D[Foliar Spray on Wheat];
        end
        subgraph Stress & Measurement
            E{Induce Drought Stress} --> F[Measure Relative Water Content];
            E --> G[Measure Final Seed Yield];
        end
        B --> C;
        D --> E;
    

• Derivative 1.3.2: Aerospace - Radiation-Resistant Polymer Composite

  • Enabling Description: A composite material for aerospace applications with enhanced resistance to radiation damage. Nicotinamide riboside chloride is incorporated at 0.5% (w/w) into a polyether ether ketone (PEEK) matrix via melt extrusion. The resulting PEEK-NRCl composite is subjected to high-energy proton bombardment (100 MeV) simulating the space radiation environment. The PEEK-NRCl composite retains 95% of its tensile strength, whereas the control PEEK material retains only 80%. The aromatic pyridinium ring of the NR cation is hypothesized to act as an energy sink, dissipating radiation energy and preventing polymer chain scission.
  • Diagram:

    classDiagram
        class Composite {
            +matrix: PEEK
            +additive: NR-Chloride
            +concentration: 0.5% w/w
        }
        class PEEK {
            -tensile_strength
        }
        class NR_Chloride {
            -aromatic_ring
        }
        Composite *-- PEEK
        Composite *-- NR_Chloride
    

• Derivative 1.3.3: Consumer Electronics - Biosensor Electrolyte

  • Enabling Description: The use of NR salts in bioelectronic sensors. An electrochemical glucose sensor is constructed with a gold electrode functionalized with glucose oxidase. The electrolyte is a hydrogel containing 10 mM nicotinamide riboside acetate. When glucose is present, its oxidation by glucose oxidase produces H₂O₂, which chemically oxidizes the dihydronicotinamide moiety of any naturally reduced NRH present in the system, or interacts electrochemically with the NR+ cation itself, leading to a measurable change in impedance that is proportional to the glucose concentration. The NR salt enhances signal stability and sensitivity compared to a simple saline electrolyte.
  • Diagram:

    sequenceDiagram
        participant Sample as Glucose
        participant Electrode as GOx-Functionalized Au
        participant Electrolyte as NR-Acetate Hydrogel
        Sample->>Electrode: Glucose Introduction
        activate Electrode
        Electrode->>Electrode: Glucose Oxidase Reaction (produces H₂O₂)
        Electrode->>Electrolyte: H₂O₂ interacts with NR+/NRH redox pair
        deactivate Electrode
        activate Electrolyte
        Electrolyte-->>Electrode: Change in Electrochemical Impedance
        deactivate Electrolyte
    

Part 2: Derivative Methods Based on Claims 13 and 18

The core of claims 13 and 18 is a method for anion exchange from a triflate salt to a desired salt X- using a nitrogen-containing cation Z+. The following disclosures expand on this process.

2.1. Integration with Emerging Tech: Intelligent Synthesis

• Derivative 2.1.1: AI-Optimized Flow Chemistry

  • Enabling Description: An autonomous system for the optimization and production of nicotinamide riboside salts. A microfluidic flow reactor is constructed with inputs for NR-triflate solution, an ammonium salt solution (e.g., ammonium lactate), and a solvent. A machine learning algorithm, specifically a Gaussian process regression model, controls the input parameters: flow rate (residence time), temperature, and reactant concentration. An in-line HPLC-MS system analyzes the reactor output for yield and purity in real-time. The algorithm uses this data to build a predictive model of the reaction landscape and intelligently selects the next set of experimental parameters to maximize purity and yield, achieving >99% purity in a continuous production mode.
  • Diagram:

    flowchart TD
        A[Start] --> B(ML Model Sets Initial Parameters);
        B --> C{Flow Reactor Synthesizes NR-Lactate};
        C --> D[In-line HPLC-MS Analyzes Output];
        D --> E{Data Feed: Yield & Purity};
        E --> F(ML Model Updates Internal Representation);
        F --> G{Predicts Optimal Next Parameters};
        G --> C;
    

• Derivative 2.1.2: Blockchain-Verified Pharmaceutical Supply Chain

  • Enabling Description: A method for ensuring the provenance and quality of NR salts. Each step of the synthesis process claimed in the '506 patent is recorded on a distributed ledger. Raw material batch numbers, the specific ammonium salt used (Z+X-), reaction parameters from an IoT-enabled reactor (temperature, pH, time), and final QC data (NMR, HPLC purity) are cryptographically signed and added as a transaction to a permissioned blockchain. A QR code on the final product allows a consumer to access this immutable record, providing full transparency and trust in the product's quality and authenticity.
  • Diagram:

    sequenceDiagram
        participant Supplier
        participant Manufacturer
        participant Blockchain
        participant Consumer
        Supplier->>Manufacturer: Provides Raw Materials with COA
        Manufacturer->>Blockchain: Record Raw Material Data
        Manufacturer->>Manufacturer: Synthesize NR-Salt (per patent method)
        Manufacturer->>Blockchain: Record Synthesis & QC Data
        Manufacturer->>Consumer: Ship Final Product with QR Code
        Consumer->>Blockchain: Scan QR Code to Verify Provenance
    

2.2. The "Inverse" or Failure Mode: Fail-Safe Synthesis

• Derivative 2.2.1: Scavenger-Assisted Purification
  • Enabling Description: A method to ensure the complete removal of the initial toxic anion. Following the anion exchange reaction of NR-triflate with ammonium chloride, the reaction mixture is passed through a column packed with a solid-supported scavenger resin, such as a quaternary ammonium-functionalized polystyrene resin (a strong anion exchanger). This resin has a high affinity for the triflate anion but not for the chloride anion. It quantitatively captures any unreacted triflate, ensuring the final eluate containing the NR-chloride product has triflate levels below the limit of detection (e.g., <1 ppm), providing a robust and scalable method for guaranteeing product safety, even with incomplete reactions.
  • Diagram:

    flowchart TD
        A[NR-Triflate + NH₄Cl Reaction Mixture] --> B[Pass through Anion Exchange Column];
        subgraph Column
            C[Resin Bed: Quaternary Ammonium Polystyrene]
        end
        B --> D{Triflate Anions Bind to Resin};
        B --> E[NR-Chloride Passes Through];
        E --> F[End: Ultra-Pure NR-Chloride Solution];
    

Part 3: Combination Prior Art Scenarios

• Scenario 3.1: Integration with OPC-UA Industrial Standard: The AI-Optimized Flow Chemistry system (Derivative 2.1.1) is implemented using the IEC 62541 OPC-UA standard. The in-line HPLC-MS, temperature sensors, and pump controllers all communicate as OPC-UA clients and servers. This allows for seamless, vendor-agnostic integration of process analytical technology with the control system, rendering the application of standard Industry 4.0 protocols to the claimed synthesis method as obvious.

• Scenario 3.2: Integration with ERC-1155 Multi-Token Standard: The Blockchain-Verified Supply Chain (Derivative 2.1.2) is enhanced using the Ethereum ERC-1155 multi-token standard. A single smart contract manages tokens for both the fungible raw materials (e.g., a token representing 1 kg of NR-triflate from a specific batch) and the non-fungible final product (an NFT representing the unique, QC-verified batch of NR-chloride). This creates a complete, tokenized representation of the entire manufacturing process on an open standard.

• Scenario 3.3: Integration with Systems Biology Markup Language (SBML): The agricultural application (Derivative 1.3.1) is optimized using a predictive metabolic model of the target crop, encoded in the open-source SBML format. The model simulates the flux through the NAD+ salvage pathway in response to varying concentrations of exogenous NR-aspartate under different simulated stress conditions (drought, salinity). The model is used to generate tailored application protocols (dosing, timing) for specific crops, rendering the use of standard in-silico modeling for optimizing the use of the claimed compounds as obvious.